Publications by authors named "F Volot"
Objectives: To assess the real-world efficacy and safety of recombinant factor IX albumin fusion protein (rIX-FP) in patients with hemophilia B (HB) in France.
Methods: Data on dosing frequency, weekly consumption, and bleeds before-and-after switching to rIX-FP, were collected from December 2021 to February 2024. Annualized (spontaneous) bleeding rates [A(s)BRs] were calculated only in patients on prophylaxis with a follow-up ≥ 6 months.
Article Synopsis
- Factor XI deficiency is a rare bleeding disorder, and it's hard to predict how much a person will bleed based on their Factor XI levels.
- A study looked at pregnant women with low Factor XI levels to see how they were managed during childbirth and their experiences with pain relief methods like epidurals and spinals.
- The results showed that a lot of women had successful pain relief procedures without complications, and it was suggested that it's safe to use these methods if Factor XI levels are above 30 IU/dL.
Article Synopsis
- Type 2 Normandy von Willebrand disease (VWD2N) is generally seen as a mild bleeding disorder treatable with desmopressin (DDAVP), but the genetic variations among patients, especially the common variant p.Arg854Gln (R854Q), can significantly influence disease severity and treatment response.
- A study involving 123 VWD2N patients analyzed their phenotype and DDAVP response based on genotype, revealing that those with R854Q alleles exhibited different clinical outcomes and bleeding symptoms compared to those without.
- The findings indicate that genetic factors, particularly the presence of the R854Q variant, affect factor VIII levels and the efficacy of DDAVP, highlighting the importance of tailored treatment approaches for V
Introduction: Bleeding severity in severe haemophilic patients, with low thrombin generation (TG) capacity, can vary widely between patients, possibly reflecting differences in tissue factor pathway inhibitor (TFPI) level.
Aim: To compare free TFPI (fTFPI) levels in patients with severe haemophilia A (sHA) and severe haemophilia B (sHB) and to investigate in these patients as a whole the relationships between bleeding and TG potential, between TG potential and fTFPI level and between fTFPI level and bleeding tendency.
Methods: Data on bleeding episodes retrospectively recorded during follow-up visits over 5-10 years were collected and used to calculate the annualised joint bleeding rate (AJBR).
Background: No F8 genetic abnormality is detected in approximately 1% to 2% of patients with severe hemophilia A (HA) using conventional genetic approaches. In these patients, deep intronic variation or F8 disrupting genomic rearrangement could be causal.
Objectives: The study aimed to identify the causal variation in families with a history of severe HA for whom genetic investigations failed.